Dr. Domchek on Promising Biomarkers in Breast Cancer

Susan Domchek, MD

Published: Tuesday, Jan 09, 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Biomarkers such as BRCA1/2 are currently used to determine treatment for patients with breast cancer, explains Domcheck.

Domcheck adds that if a patient is microsatellite instability-high (MSI-H), then that patient can receive pembrolizumab (Keytruda) regardless of tumor site.

SELECTED
LANGUAGE

SEE ALL VIDEOS FROM: Susan Domchek, MD

View more on OncLive TV >>>

Trending Now

FDA Approves Ruxolitinib for Steroid-Refractory Acute GVHD

Folate Receptor Alpha as a Therapeutic Target for Ovarian Cancer

How the Treatment of Stage III NSCLC Has Changed

TAS-102 Expands Arsenal in Gastric Cancer, But Long Road Ahead for Research

MCL Landscape Rapidly Evolving With Promising Approaches on Horizon

Experts Say DCIS Requires Focus on Genomics and Microenvironment

Pembrolizumab Misses OS Endpoint in Metastatic TNBC

Low-Fat Diet Could Reduce Risk of Death From Breast Cancer

CDK4/6 Inhibitors Firmly Established in HR+ Breast Cancer, OS Data Awaited

Related Videos

Implications for Systemic Therapy in Breast Cancer

Novel Therapies in TNBC: Real-World Experience

I-O + PARP Inhibition for Triple-Negative Breast Cancer

Checkpoint Inhibitors for Triple-Negative Breast Cancer

View Conference Coverage

2019 ASCO Annual Meeting

2019 State of the Science Summit on Genitourinary Cancers in Needham

2019 State of the Science Summit on Hematologic Malignancies in Wisconsin

2019 European Lung Cancer Congress

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?	May 31, 2019	1.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast Cancer	May 31, 2019	1.5